TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non needle control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Acupuncture - Standardized Points; Type: SHAM_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Accupunture - Experimental Points; Type: EXPERIMENTAL; Interventions: Procedure: Accupuncture | Intervention Type: PROCEDURE; Name: Accupuncture; Assigned to Arm(s): Accupunture - Experimental Points, Acupuncture - Standardized Points, non needle control
B: Arm Label: Fecal Occult Blood Test; Type: ACTIVE_COMPARATOR; Interventions: Other: Fecal occult blood test | Arm Label: Virtual Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Virtual colonoscopy | Arm Label: Optical Colonoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Optical colonoscopy | Intervention Type: OTHER; Name: Fecal occult blood test; Assigned to Arm(s): Fecal Occult Blood Test | Intervention Type: PROCEDURE; Name: Virtual colonoscopy; Assigned to Arm(s): Virtual Colonoscopy | Intervention Type: PROCEDURE; Name: Optical colonoscopy; Assigned to Arm(s): Optical Colonoscopy
C: Intervention Type: BEHAVIORAL; Name: Familial risk assessment and personalized prevention messages; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
B: Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
D: Arm Label: Early postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (<3-day postpartum) | Arm Label: Late postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (6 wk postpartum) | Arm Label: Early & late postpartum vitamin A suppl; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A (<3-day and 6 wk postpartum) | Arm Label: No postpartum vitamin A suppl.; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (<3-day postpartum); Assigned to Arm(s): Early postpartum vitamin A suppl. | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (6 wk postpartum); Assigned to Arm(s): Late postpartum vitamin A suppl. | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A (<3-day and 6 wk postpartum); Assigned to Arm(s): Early & late postpartum vitamin A suppl | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): No postpartum vitamin A suppl.

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Brief Summary: The purpose of this trial is to determine whether providing women with a weekly oral supplement of vitamin A, either preformed or as beta-carotene, at a dosage equivalent to a recommended intake from early pregnancy through three months postpartum, can reduce the risk of maternal mortality, fetal loss, or infant mortality.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin A or Beta-Carotene Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin A or Beta-Carotene Supplements; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Vitamin A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: retinyl palmitate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: retinyl palmitate; Assigned to Arm(s): Vitamin A | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation Research of the Nutrition Interventions in the INHP II Areas of CARE India
Brief Summary: This study is designed to evaluate the effectiveness of CARE India's Integrated Nutrition and Health Program (INHP II) to reduce malnutrition among children 0-23 months of age.


Options:
A: Intervention Type: BEHAVIORAL; Name: Maternal nutrition and infant feeding advice; Assigned to Arm(s): N/A
B: Arm Label: Arm 1: BCC+PNS+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 2: BCC+PNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrient supplement to pregnant women (PNS) | Arm Label: Arm 3: BCC+CNS; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC), Dietary Supplement: Nutrienr supplement to children 6m to 2 years | Arm Label: Arm 4: BCC only; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition-specific Behaviour change communication (BCC) | Arm Label: Arm 5: comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nutrition-specific Behaviour change communication (BCC); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS, Arm 3: BCC+CNS, Arm 4: BCC only | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrient supplement to pregnant women (PNS); Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 2: BCC+PNS | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrienr supplement to children 6m to 2 years; Assigned to Arm(s): Arm 1: BCC+PNS+CNS, Arm 3: BCC+CNS
C: Arm Label: Nutrition messages; Type: EXPERIMENTAL; Interventions: Behavioral: SMS | Arm Label: General health messages; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS | Intervention Type: BEHAVIORAL; Name: SMS; Assigned to Arm(s): General health messages, Nutrition messages
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Arm Label: 30 % ethanol/ 4 % sodium citrate group; Type: EXPERIMENTAL; Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution | Arm Label: Heparin 1000 U/ml; Type: EXPERIMENTAL; Interventions: Drug: Heparin 1000 u / ml | Intervention Type: OTHER; Name: 30 % ethanol / 4% sodium citrate catheter locking solution; Assigned to Arm(s): 30 % ethanol/ 4 % sodium citrate group | Intervention Type: DRUG; Name: Heparin 1000 u / ml; Assigned to Arm(s): Heparin 1000 U/ml
B: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily
C: Intervention Type: DRUG; Name: taurolidine; Assigned to Arm(s): N/A
D: Arm Label: AAT-023 (Zuragen Arm); Type: EXPERIMENTAL; Interventions: Device: AAT-023 solution (Zuragen) | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DEVICE; Name: AAT-023 solution (Zuragen); Assigned to Arm(s): AAT-023 (Zuragen Arm) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Arm Label: 30 % ethanol/ 4 % sodium citrate group; Type: EXPERIMENTAL; Interventions: Other: 30 % ethanol / 4% sodium citrate catheter locking solution | Arm Label: Heparin 1000 U/ml; Type: EXPERIMENTAL; Interventions: Drug: Heparin 1000 u / ml | Intervention Type: OTHER; Name: 30 % ethanol / 4% sodium citrate catheter locking solution; Assigned to Arm(s): 30 % ethanol/ 4 % sodium citrate group | Intervention Type: DRUG; Name: Heparin 1000 u / ml; Assigned to Arm(s): Heparin 1000 U/ml
B: Arm Label: AAT-023 (Zuragen Arm); Type: EXPERIMENTAL; Interventions: Device: AAT-023 solution (Zuragen) | Arm Label: Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Intervention Type: DEVICE; Name: AAT-023 solution (Zuragen); Assigned to Arm(s): AAT-023 (Zuragen Arm) | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Heparin
C: Intervention Type: DRUG; Name: taurolidine; Assigned to Arm(s): N/A
D: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Thrombosis With Implantable Devices for Central Venous Access in Cancer Patients : Phase III Randomised Study
Brief Summary: This is a Phase III open-labed, multicenter, prospective, randomised study, and comparative 3-arms of 140 patients (i.e. 420 total patients).

Study period (date of first inclusion/last inclusion): 3 years Treatment period : 3 months


Options:
A: Arm Label: High Risk for VTE recieving dalteparin; Type: EXPERIMENTAL; Interventions: Drug: dalteparin injection | Arm Label: High Risk for VTE No therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Low Risk for VTE; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: dalteparin injection; Assigned to Arm(s): High Risk for VTE recieving dalteparin
B: Arm Label: lack of drug prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: HBPM 2500 UI anti Xa in one subcutaneous injection per day; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Arm Label: warfarine 1mg daily; Type: EXPERIMENTAL; Interventions: Drug: warfarine - low molecular heparin | Intervention Type: DRUG; Name: warfarine - low molecular heparin; Assigned to Arm(s): HBPM 2500 UI anti Xa in one subcutaneous injection per day, warfarine 1mg daily
C: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)
D: Arm Label: short heparin; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: extended heparin; Type: EXPERIMENTAL; Interventions: Drug: Heparin, Low-Molecular-Weight | Intervention Type: DRUG; Name: Heparin, Low-Molecular-Weight; Assigned to Arm(s): extended heparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Stem Cell Transplantation in Acute Myocardial Infarction
Brief Summary: Objectives

Intracoronary transplantation of different cell populations have been used in acute myocardial infarction (AMI) with promising results. The primary objective of the ASTAMI study is to test whether intracoronary transplantation of autologous mononuclear bone marrow cells (mBMC) improve left ventricular ejection fraction (LVEF) after anterior wall AMI.

Design

The ASTAMI study is a randomized, controlled, prospective study. One hundred patients with acute anterior wall ST-elevation myocardial infarction (STEMI) treated with acute PCI are randomized in a 1:1 way to either intracoronary transplantation of autologous mBMC 5-8 days after PCI or to control. Left ventricular function, exercise capacity, biochemical status, functional class, quality of life and complications are validated at baseline and during a 12-month follow up.


Options:
A: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
B: Intervention Type: GENETIC; Name: Intracoronary aotologous stem cell transplantation; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Early; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Arm Label: Late; Type: EXPERIMENTAL; Interventions: Procedure: intracoronary bone marrow cells infusion | Intervention Type: PROCEDURE; Name: intracoronary bone marrow cells infusion; Assigned to Arm(s): Early, Late
D: Arm Label: Cardiac Stem Cell Treatment - Group 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous stem cell infusion | Arm Label: Cardiac Stem Cell Treatment -Group 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous stem cell infusion | Arm Label: Observation (Control Group); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous stem cell infusion; Assigned to Arm(s): Cardiac Stem Cell Treatment - Group 1 | Intervention Type: BIOLOGICAL; Name: Autologous stem cell infusion; Assigned to Arm(s): Cardiac Stem Cell Treatment -Group 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effectiveness of Shortwave Diathermy in Knee Osteoarthritis: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether shortwave diathermy is effective in reducing knee pain and increasing function of the patients with knee osteoarthritis.


Options:
A: Arm Label: active; Type: ACTIVE_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Wearable pulsed electromagnetic fields | Intervention Type: DEVICE; Name: Wearable pulsed electromagnetic fields; Assigned to Arm(s): active, placebo
B: Arm Label: High dose PSW groups; Type: EXPERIMENTAL; Interventions: Device: Pulsed short wave | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Pulsed short wave | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Pulsed short wave; Assigned to Arm(s): High dose PSW groups, Placebo
C: Arm Label: MWM treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: MWM Treatment | Arm Label: MWM sham; Type: SHAM_COMPARATOR; Interventions: Other: MWM Sham | Intervention Type: OTHER; Name: MWM Treatment; Assigned to Arm(s): MWM treatment | Intervention Type: OTHER; Name: MWM Sham; Assigned to Arm(s): MWM sham
D: Arm Label: Shortwave diathermy; Type: EXPERIMENTAL; Interventions: Device: Shortwave diathermy | Arm Label: control; Type: SHAM_COMPARATOR; Interventions: Device: Shortwave diathermy | Intervention Type: DEVICE; Name: Shortwave diathermy; Assigned to Arm(s): Shortwave diathermy, control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Multicenter Trial Testing the Antiproteinuric Effect of Statins Added to Combined ACE-inhibitor and Angiotensin Receptor Antagonist Therapy in Proteinuric, Chronic Nephropathies
Brief Summary: End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have increased morbidity and mortality mostly because of a dramatic excess of cardiovascular disease. Thus, preventing or limiting the progression of chronic nephropathies, in addition to limit the incidence of ESRD, may also postpone death. Drugs that inhibit the renin angiotensin system, such as Angiotensin-Converting-Enzyme inhibitors (ACEi) and Angiotensin II receptor antagonists (ATA), are reno- and cardio-protective in the long-term. There are data that statins,in addition to limit cardiovascular events may have specific reno-protective properties.

Thus we designed a study aimed to evaluate whether statins associated to ACEi and ATA may have an additional reno-protective effect.

ESPLANADE is a multicenter, prospective, randomized, parallel group study in which, after 2 months treatment with ACEi and ATA, two groups of 90 patients, with or without type 2 diabetes, are randomized to 6 months Fluvastatin (40 or 80 mg/day) treatment YES or NO.Twenty Italian Nephrology Units are involved in the trial. The study is fully coordinated by the Clinical Research Center for Rare Disease Aldo e Cele Daccò, Villa Camozzi, Ranica.


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Unikalk | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Unikalk; Assigned to Arm(s): Placebo
B: Arm Label: standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: standard therapy | Arm Label: fluvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluvastatin | Intervention Type: DRUG; Name: Fluvastatin; Assigned to Arm(s): fluvastatin | Intervention Type: DRUG; Name: standard therapy; Assigned to Arm(s): standard therapy
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin, Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sacral Nerve Stimulation for Anal Incontinence and Bowel Control
Brief Summary: Multicenter European study to evaluate efficacy and safety of sacral nerve stimulation with InterStim Therapy to treat fecal incontinence or constipation


Options:
A: Arm Label: Blinded injection of NASHA/Dx gel at randomization.; Type: EXPERIMENTAL; Interventions: Device: NASHA/Dx (Solesta) Gel | Arm Label: Blinded sham inject. at randomization; Type: SHAM_COMPARATOR; Interventions: Device: Sham Injection | Arm Label: Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo.; Type: OTHER; Interventions: Device: NASHA/Dx (Solesta) Gel, Device: Sham Injection | Intervention Type: DEVICE; Name: NASHA/Dx (Solesta) Gel; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded injection of NASHA/Dx gel at randomization. | Intervention Type: DEVICE; Name: Sham Injection; Assigned to Arm(s): Blinded Sham Inject. at Randomization + NASHA/Dx Gel at 6 mo., Blinded sham inject. at randomization
B: Arm Label: InterStim therapy; Type: EXPERIMENTAL; Interventions: Device: Type: Implantable neurostimulator; InterStim | Intervention Type: DEVICE; Name: Type: Implantable neurostimulator; InterStim; Assigned to Arm(s): InterStim therapy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prucalopride | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Prucalopride; Assigned to Arm(s): 2
D: Arm Label: Sensory threshold - Amplitude; Type: ACTIVE_COMPARATOR; Interventions: Device: Sensory Threshold | Arm Label: 25% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 75% of sensory threshold - Amplitude | Arm Label: 50% below sensory threshold - Amplitude; Type: EXPERIMENTAL; Interventions: Device: 50% of sensory threshold - Amplitude | Intervention Type: DEVICE; Name: Sensory Threshold; Assigned to Arm(s): Sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 75% of sensory threshold - Amplitude; Assigned to Arm(s): 25% below sensory threshold - Amplitude | Intervention Type: DEVICE; Name: 50% of sensory threshold - Amplitude; Assigned to Arm(s): 50% below sensory threshold - Amplitude

Answer: B